Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBITDA (2019 - 2025)

Historic EBITDA for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$26.2 million.

  • Silence Therapeutics' EBITDA rose 1037.6% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1183.47%. This contributed to the annual value of -$63.3 million for FY2024, which is 284.72% down from last year.
  • Latest data reveals that Silence Therapeutics reported EBITDA of -$26.2 million as of Q3 2025, which was up 1037.6% from -$24.0 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year EBITDA high stood at -$12880.5 for Q1 2021, and its period low was -$29.3 million during Q3 2024.
  • Its 5-year average for EBITDA is -$16.4 million, with a median of -$16.1 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 13704901.42% in 2021, then surged by 7363.4% in 2024.
  • Quarter analysis of 5 years shows Silence Therapeutics' EBITDA stood at -$15.2 million in 2021, then increased by 15.32% to -$12.9 million in 2022, then decreased by 28.39% to -$16.5 million in 2023, then skyrocketed by 73.63% to -$4.4 million in 2024, then plummeted by 503.03% to -$26.2 million in 2025.
  • Its EBITDA was -$26.2 million in Q3 2025, compared to -$24.0 million in Q2 2025 and -$28.4 million in Q1 2025.